Merck, Allergan Suggested As Suitors But Biogen's Attractiveness Under Question

Biogen's share price has risen on speculation that it is an acquisition target for Merck & Co and Allergan. But with a number of uncertainties hanging over the company, can Biogen negotiate a premium price?